Compare LMAT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | ADMA |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2006 | 2012 |
| Metric | LMAT | ADMA |
|---|---|---|
| Price | $94.30 | $8.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $105.80 | $25.67 |
| AVG Volume (30 Days) | 292.9K | ★ 3.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | N/A |
| EPS | ★ 0.68 | 0.19 |
| Revenue | ★ $249,602,000.00 | $42,219,783.00 |
| Revenue This Year | $14.21 | $27.46 |
| Revenue Next Year | $8.88 | $22.11 |
| P/E Ratio | $138.13 | ★ $45.89 |
| Revenue Growth | 13.53 | ★ 43.85 |
| 52 Week Low | $79.01 | $7.21 |
| 52 Week High | $118.01 | $20.46 |
| Indicator | LMAT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 52.30 |
| Support Level | $82.26 | $7.38 |
| Resistance Level | $97.83 | $8.90 |
| Average True Range (ATR) | 3.02 | 0.33 |
| MACD | 0.63 | 0.12 |
| Stochastic Oscillator | 61.26 | 67.24 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.